Hematologic Neoplasms, Solid Tumor
Conditions
Brief summary
The ACC Preclinical Research Platform for Precision Oncology is a retrospective and prospective observational study focused on the implementation and validation of the application of PDCM (Patient Derived Cancer Models) generated from tissues or cells of patients with neoplastic disease, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments.
Detailed description
This is a retrospective and prospective observational study, focused on the implementation and validation of the application of PDCM, generated from tissue or cells of patients, including paediatric patients, with solid and haematological malignancies, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments. An up-to-date database of all PDCMs available at the participating italian hospitals will be generated and enriched with new models generated during the course of the project. The sharing of models and procedures between the different hospitals will facilitate their molecular and phenotypic characterisation, also in parallel with the tumours of origin, as well as their validation as tools for testing the efficacy of drugs for precision medicine. By establishing common workflows and standards and performing cross-validation experiments it is planned to build a network of reference centres as a resource for drug screening on 2D and 3D models.
Interventions
None listed
Sponsors
Alleanza Contro il Cancro
Fondazione del Piemonte per l'Oncologia
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients, including paediatric patients, with solid and haematological malignancies for whom tissue or tumour cell material is available.
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of PDCM (patient derived cancer models) | 12 months | PDCM will be generated from tissues and cells |
| number of Whole Exome Sequencing (WES) e RNA-seq performed | 12 months | WES and RNA seq will be performed on tissues and blood |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| number of PDCM shared within the network | 12 months | PDCM will be generated from tissues and cells and shared within the network |
Countries
Italy
Contacts
Primary ContactEnzo Medico, MD
Backup ContactMarco Asioli, BSc
Outcome results
None listed